aptaTargets News and Updates

R&D Programs

R&D Programs

Date Name

Desc Asc

Jul, 2025

ApTOLL’s secondary analysis data of APRIL 1b/2a trial published in ‘Stroke’

May, 2025

aptaTargets transferred ApTOLL to Merck

Dec, 2024

aptaTargets awarded with the Programa Cheque Innovación 2024 from the Community of Madrid

Jun, 2024

A new study shows the cerebroprotective effects of ApTOLL on mice with acute ischemic stroke

May, 2024

Preclinical studies validate the potential of ApTOLL to reduce inflammation and regenerate myelin in models of multiple sclerosis

May, 2024

aptaTargets CSO Macarena Hernández will speak at the 10th European Stroke Conference

Mar, 2024

aptaTargets secures €2.5 million from the EU to initiate the Phase 2b clinical trial in patients with ischemic stroke

Feb, 2024

aptaTargets receives a €1.9 million grant from the Community of Madrid

Jan, 2024

aptaTargets receives €4 M for the Phase 2b clinical trial with ApTOLL in patients with ischemic stroke

Oct, 2023

aptaTargets participates in a study with world leaders in stroke to improve enrollment in clinical trials

Jun, 2023

‘JAMA Neurology’ publishes the results from Phase 1b/2a clinical trial of the neuroprotective drug ApTOLL for ischemic stroke

Jun, 2023

Doctor Marc Ribó receives an award from the Spanish Society of Neurology

Mar, 2023

aptaTargets receives PRIME designation from the European Medicines Agency for ApTOLL in ischemic stroke

Feb, 2023

ApTOLL reduces mortality from 18% to 5% in a Phase 1b/2a trial in ischemic stroke patients

Jan, 2023

aptaTargets, IRYCIS, IDIBELL, IdISSC and ISABIAL awarded €2.5 million grant to evaluate ApTOLL for acute myocardial infarction

Dec, 2022

aptaTargets, VHIR, IDIBELL, IGTP and IDIBGI awarded €3.5 million grant to evaluate ApTOLL in ambulances

Oct, 2022

aptaTargets announces positive preliminary data from the ApTOLL Phase 2a clinical trial for stroke

Sep, 2022

aptaTargets to present ApTOLL at the Oligonucleotide Therapeutics Conference 2022 in United Kingdom

Jun, 2022

aptaTargets visits Singapore’s healthcare ecosystem with ICEX and MedTech Actuator

Jun, 2022

aptaTargets presents ApTOLL at the International Oligonucleotides and Peptides Conference 2022

Apr, 2022

aptaTargets completes recruitment for Phase 2a clinical trial of ApTOLL in stroke

Apr, 2022

aptaTargets’ Phase 1b clinical data for ApTOLL published in ‘Molecular Therapy: Nucleic Acids’ journal

Mar, 2022

aptaTargets announces first patient dosed in the clinical trial of ApTOLL for COVID-19

Feb, 2022

aptaTargets joins a consortium to accelerate RNA-based therapies in Spain

Jan, 2022

aptaTargets to present new ApTOLL clinical data at the International Stroke Conference 2022

Jan, 2022

aptaTargets tests an aptamer in COVID-19 patients

Dec, 2021

aptaTargets awarded with the Programa Cheque Innovación 2021 from Comunidad de Madrid

Oct, 2021

CDTI-Cervera program

aptaTargets has been awarded by the CDTI-Cervera program to investigate new biomarkers associated to the biological effect of ApTOLL.

Jun, 2021

APRIL trial update: completed enrollment and dosing for Phase 1b

May, 2021

CDTI-PID program

aptaTargets gets additional funding from the CDTI, to study the protective effect of ApTOLL in Acute Respiratory Distress Syndrome (ARDS).

(EXP-00132712/IDI-20201155)

Apr, 2021

APRIL trial (Acute Ischemic Stroke) gets authorization by the ANSM (France) and the BfArM (Germany)

Oct, 2020

aptaTargets starts Phase 1b/2a clinical trial with ApTOLL in stroke patients

Oct, 2020

aptaTargets closes a second round of €5 million

Inveready and the CDTI through the INNVIERTE program will invest €2.3 million of capital. This amount will be complemented by €2.7 million through other instruments and public funds that have already been obtained. With these funds, aptaTargets plans to advance up to a clinical proof of concept in acute ischemic stroke patients.

Aug, 2020

ApTOLL efficacy in myocardial infarction

Ramirez-Carracedo et al. Targeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.

Biomolecules. Aug 9;10(8):1167. doi:10.3390/biom10081167.

Jul, 2020

Authorization to start the APRIL trial

The Spanish regulatory agency has approved the APRIL clinical trial, a Phase 1b/2a study to assess the safety and efficacy of ApTOLL in acute ischemic stroke patients.

Jul, 2020

RETOS funding for the ApTOLL stroke program

Consortium formed by aptaTargets and the Vall d’Hebron Hospital (VHIR) have been awarded by the Retos-Colaboracion program. The project and the €1,4 million will be focused on the clinical development of ApTOLL. The Retos-Colaboracion is a collaborative program of the Spanish Ministry of Science and Innovation, within the objective of promoting the technological development, innovation, and research.

(RTC2019-006795-1)

Jun, 2020

Torres Quevedo grant

aptaTargets gets a grant from the Torres Quevedo Program.

(PTQ2019-010411)

Mar, 2020

aptaTargets announces completion of enrollment in the Phase I study of ApTOLL in healthy volunteers

aptaTargets has completed the enrollment of the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

Jun, 2019

EIT Health

aptaTargets has been awarded with the Bridgehead Program.

First Patient in the ApTOLL-FIH-01 trial: <span class="light">a Phase I trial in healthy volunteers</span>

Jun, 2019

First Patient in the ApTOLL-FIH-01 trial: a Phase I trial in healthy volunteers

aptaTargets has started the First-in-human ApTOLL-FIH-01 trial, a dose ascending, randomized, placebo-controlled clinical trial to assess tolerability and pharmacokinetics of ApTOLL in healthy volunteers. ApTOLL is a DNA aptamer which has been selected to antagonize TLR4 with high specificity and, therefore, to block the inflammatory response released after the stroke onset and substantially reducing brain damage.

News and Events

R&D Programs